Nonoperating Income (Expense) in USD of RELMADA THERAPEUTICS, INC. from Q3 2013 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
RELMADA THERAPEUTICS, INC. quarterly/annual Nonoperating Income (Expense) history and change rate from Q3 2013 to Q3 2025.
  • RELMADA THERAPEUTICS, INC. Nonoperating Income (Expense) for the quarter ending 30 Sep 2025 was $236K, a 81.6% decline year-over-year.
  • RELMADA THERAPEUTICS, INC. Nonoperating Income (Expense) for the twelve months ending 30 Sep 2025 was $1.67M, a 67.7% decline year-over-year.
  • RELMADA THERAPEUTICS, INC. annual Nonoperating Income (Expense) for 2024 was $3.91M, a 20.3% decline from 2023.
  • RELMADA THERAPEUTICS, INC. annual Nonoperating Income (Expense) for 2023 was $4.91M, a 16.8% increase from 2022.
  • RELMADA THERAPEUTICS, INC. annual Nonoperating Income (Expense) for 2022 was $4.21M.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Change (%)
Nonoperating Income (Expense), Annual (USD)
Nonoperating Income (Expense), YoY Annual Change (%)

RELMADA THERAPEUTICS, INC. Quarterly Nonoperating Income (Expense) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $1.67M $236K -$1.05M -81.6% 01 Jul 2025 30 Sep 2025 10-Q 13 Nov 2025
Q2 2025 $2.72M $355K -$696K -66.2% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025
Q1 2025 $3.41M $659K -$501K -43.2% 01 Jan 2025 31 Mar 2025 10-Q 12 May 2025
Q4 2024 $3.91M $418K -$1.25M -74.9% 01 Oct 2024 31 Dec 2024 10-K 27 Mar 2025
Q3 2024 $5.16M $1.28M +$592K +85.8% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2025
Q2 2024 $4.57M $1.05M +$327K +45.2% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025
Q1 2024 $4.24M $1.16M -$672K -36.7% 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025
Q4 2023 $4.91M $1.66M +$906K +120% 01 Oct 2023 31 Dec 2023 10-K 27 Mar 2025
Q3 2023 $4M $691K +$1.37M 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024
Q2 2023 $2.63M $724K -$4.85M -87% 01 Apr 2023 30 Jun 2023 10-Q 07 Aug 2024
Q1 2023 $7.49M $1.83M +$3.28M 01 Jan 2023 31 Mar 2023 10-Q 08 May 2024
Q4 2022 $4.21M $758K +$954K 01 Oct 2022 31 Dec 2022 10-K 19 Mar 2024
Q3 2022 $3.25M -$682K -$729K -1537% 01 Jul 2022 30 Sep 2022 10-Q 08 Nov 2023
Q2 2022 $3.98M $5.58M +$5.67M 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023
Q1 2022 -$1.69M -$1.45M -$1.64M -862% 01 Jan 2022 31 Mar 2022 10-Q 05 May 2022
Q4 2021 -$48.3K -$196K -$357K -221% 01 Oct 2021 31 Dec 2021 10-K 23 Mar 2023
Q3 2021 $309K $47.4K -$234K -83.1% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022
Q2 2021 $542K -$90.1K -$1.73M -105% 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022
Q1 2021 $2.27M $190K +$889K 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022
Q4 2020 $1.38M $161K +$124K +334% 01 Oct 2020 31 Dec 2020 10-K 25 Mar 2022
Q3 2020 $1.26M $281K +$243K +641% 01 Jul 2020 30 Sep 2020 10-Q 12 Nov 2021
Q2 2020 $1.01M $1.64M +$1.63M +12400% 01 Apr 2020 30 Jun 2020 10-Q 10 Aug 2021
Q1 2020 -$611K -$699K -$715K -4485% 01 Jan 2020 31 Mar 2020 10-Q 12 May 2021
Q4 2019 $104K $37.1K +$3.69M 01 Oct 2019 31 Dec 2019 10-K 24 Mar 2021
Q3 2019 -$3.58M $37.9K +$1.01M 01 Jul 2019 30 Sep 2019 10-Q 12 Nov 2020
Q2 2019 -$4.59M $13.1K +$604K 01 Apr 2019 30 Jun 2019 10-Q 12 Aug 2020
Q1 2019 -$5.19M $15.9K +$668K 01 Jan 2019 31 Mar 2019 10-Q 15 May 2020
Q4 2018 -$5.86M -$3.65M -$3.68M -12586% 01 Oct 2018 31 Dec 2018 10-Q 13 Feb 2019
Q3 2018 -$2.18M -$969K -$139K -16.7% 01 Jul 2018 30 Sep 2018 10-Q 13 Nov 2019
Q2 2018 -$2.04M -$591K 01 Apr 2018 30 Jun 2018 10-KT 26 Mar 2020
Q1 2018 -$652K 01 Jan 2018 31 Mar 2018 10-Q 15 May 2019
Q4 2017 $29.2K 01 Oct 2017 31 Dec 2017 10-Q 13 Feb 2019
Q3 2017 -$830K 01 Jul 2017 30 Sep 2017 10-Q 13 Nov 2018
Q1 2015 $2.1M -$5.1M -70.8% 01 Jan 2015 31 Mar 2015 10-Q 15 May 2015
Q4 2014 $9.84M +$9.95M 01 Oct 2014 31 Dec 2014 10-Q 13 Feb 2015
Q3 2014 -$26.1M -$25M -2311% 01 Jul 2014 30 Sep 2014 10-Q 07 Nov 2014
Q1 2014 $7.21M 01 Jan 2014 31 Mar 2014 10-Q 15 May 2015
Q4 2013 -$112K 01 Oct 2013 31 Dec 2013 10-Q 13 Feb 2015
Q3 2013 -$1.08M 01 Jul 2013 30 Sep 2013 10-Q 07 Nov 2014

RELMADA THERAPEUTICS, INC. Annual Nonoperating Income (Expense) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $3.91M -$999K -20.3% 01 Jan 2024 31 Dec 2024 10-K 27 Mar 2025
2023 $4.91M +$705K +16.8% 01 Jan 2023 31 Dec 2023 10-K 27 Mar 2025
2022 $4.21M +$4.25M 01 Jan 2022 31 Dec 2022 10-K 19 Mar 2024
2021 -$48.3K -$1.43M -103% 01 Jan 2021 31 Dec 2021 10-K 23 Mar 2023
2020 $1.38M +$1.28M +1228% 01 Jan 2020 31 Dec 2020 10-K 25 Mar 2022
2019 $104K +$2.15M 01 Jan 2019 31 Dec 2019 10-K 24 Mar 2021
2018 -$2.04M -$2.98M -319% 01 Jul 2017 30 Jun 2018 10-KT 26 Mar 2020
2017 $932K 01 Jul 2016 30 Jun 2017 10-K 28 Sep 2018
* An asterisk sign (*) next to the value indicates that the value is likely invalid.